All Community pharmacist articles – Page 8
-
NewsBritons responding to Omicron surge with vaccines and home testing
Between 15 December 2021 and 3 January 2022, 66% of British adults said they had received two doses as well as a booster jab, up from 46% in the first half of December
-
Independent professional body guideline
FSRH CHC guideline
This concise updated summary of the FSRH combined hormonal contraception guideline covers use, effectiveness, non-contraceptive benefits, and risks
-
News
Blood test accurately detects cancer in people with nonspecific symptoms
Evidence suggests that a new diagnostic blood test is able to detect cancer and identify metastatic disease in patients with nonspecific symptoms
-
News
Simple blood test could identify depression and measure treatment response
A new study suggests a simple blood test could be developed to identify depression and measure antidepressant response
-
News
Hospitalisation risk from Omicron variant around one-third that of Delta
An analysis from the UK Health Security Agency has found that vaccine effectiveness against hospitalisation with the Omicron variant of COVID-19 is significantly lower than that against the Delta variant, and wanes rapidly
-
News
MHRA approves third COVID antiviral pill
Paxlovid is approved to treat patients with mild-to-moderate COVID-19 infection who are at risk of developing more severe disease
-
Independent professional body guideline
BASHH STIs in young people guideline
Covering assessment, safeguarding, and management of STIs and related conditions in children and young people
-
News
MHRA approves licence extension for breast cancer drug alpelisib
The drug can now be used in combination with fulvestrant to treat hormone receptor positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation in men and postmenopausal women
-
News
Omicron numbers continue to rise over Christmas, as the Government adopts JCVI recommendations to vaccinate vulnerable children
There are no promises from Health Secretary Sajid Javid about whether more restrictions will come in January, as latest figures show that Christmas day COVID-19 cases reached a December high
-
News
UK researchers find way to boost emerging breast cancer drug’s effectiveness
Augmenting investigational drug xentuzumab could boost oestrogen receptor-positive breast cancer cell death, according to new findings
-
News
Omicron studies suggest lower COVID-19 hospitalisation rates than Delta
Small population studies in England and Scotland suggest a reduced risk of hospitalisation from the Omicron variant of between 40 and 68%
-
NICE guideline
NICE headache guideline
This easy-to-read summary of NICE's guideline explores the diagnosis and management of tension, migraine, cluster, and medication overuse headaches
-
News
JCVI approves COVID-19 vaccine for at-risk primary school children, and boosters for some teenagers
The JCVI has recommended the rollout of low-dose COVID-19 vaccines to vulnerable 5–11 year olds, and that boosters be given to 16–17 year olds and at-risk younger teenagers
-
News
Vaccination programme expands to children aged 12–15 years for second jab, with rough sleepers also targeted
Booking for a second NHS COVID-19 vaccine opened to 12–15 year olds this week, as plans to vaccinate the homeless also get a funding boost
-
News
Dr Samantha Roberts appointed NICE Chief Executive
The new incumbent will take over from Professor Gillian Leng in February next year
-
News
Data show little improvement in patients with long COVID after 1 year
The study did, however, identify a number of modifiable factors and potential treatment targets that may improve outcomes
-
News
Trial begins for needle-free COVID-19 vaccine
The intradermal needle-free injection system may boost vaccination uptake in individuals with a fear of needles
-
News
Outrage over dapagliflozin withdrawal for type 1 diabetes in EU
AstraZeneca said that the decision is not motivated by safety concerns, but that an increased risk of diabetic ketoacidosis may cause ‘confusion’ among clinicians using the drug to treat other indications
-
News
New data dulls enthusiasm for first COVID-19 oral treatment
Data analysis puts the efficacy of molnupiravir in reducing the risk of hospitalisation and death from COVID-19 at around 20% lower than originally believed
-
News
NICE releases its first pelvic floor dysfunction guideline, targeting women aged 12 and over
NICE has published the first guideline for prevention and non-surgical management of pelvic floor dysfunction, which emphasises the importance of raising awareness and early intervention
